Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

Phase 2

• Conditions: Central Retinal Vein Occlusion
• Interventions: Drug: Triamcinolone Acetonide; Drug: Bevasizumab

• Registration Number: NCT01178697
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-01
• Study Start: 2010-01
• Study First Submitted: 2010-08-02
• Study First Submitted QC: 2010-08-09
• Last Update Submitted: 2010-08-09
• Study First Posted: 2010-08-10
• Last Update Posted: 2010-08-10
• Primary Completion: 2010-09
• Study Completion: 2010-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Recent onset (less than 3 months) central retinal vein occlusion

Exclusion Criteria

• Any previous intervention

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Intravitreal triamcinolone	Triamcinolone Acetonide	-
Intravitreal bevasizumab	Bevasizumab	-

Primary Outcome Measures

Name	Time	Method
Visual acuity	6 months

Secondary Outcome Measures

Name	Time	Method
central macular thickness	6 months

Trial Locations

Locations (1)

Imam Hossein medical center; 🇮🇷 Tehran, Iran, Islamic Republic of